Botulinum toxin-B and the management of hyperhidrosis

• Published in: Clinics in dermatology 2004, Vol.22 (1), p.60-65
• Main Authors: Baumann, Leslie S, Halem, Monica L
• Format: Article
• Language: English
• Subjects: Axilla; Botulinum Toxins - administration & dosage; Botulinum Toxins - adverse effects; Botulinum Toxins, Type A; Hand; Humans; Hyperhidrosis - drug therapy; Neuromuscular Agents - administration & dosage; Neuromuscular Agents - adverse effects
• ISSN: 0738-081X; 1879-1131
• DOI: 10.1016/j.clindermatol.2003.11.001

A new serotype of botulinum toxin has recently arrived in the US. Botulinum toxin type B (BTX-B), known as Myobloc in the United States and as Neurobloc in Europe, is one of seven different antigenic members of the botulinum toxin family, five of which the human nervous system is susceptible to. Like botulinum toxin type A (BTX-A), BTX-B has been used for a myriad of both dermatologic and nondermatologic problems since its recent approval by the FDA for the treatment of cervical dystonia in December 2000. It is currently not approved however, for a cosmetic use but has been used for this purpose in an “off-label” fashion. It has followed in the therapeutic footsteps of BTX-A in the prevention and treatment of facial wrinkles such as crow's feet and glabellar frown lines. In addition, one of its current and popular uses is in the management of hyperhidrosis, a disease in search of a long needed treatment. This past year researchers have been investigating the efficacy as well as defining the dosing and application regiments of BTX-B in the treatment of hyperhidrosis. In addition, recent studies have been examining its side effect profile, which may be very different than that seen with BTX-A. There are only a handful of studies in the literature examining the cosmetic applications of BTX-B. This chapter will review what is currently known about BTX-B and its current use in regards to the treatment of hyperhidrosis.